Innovator’s Pitch Challenge Winners at RESI Europe

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

At RESI Europe 2024 in Barcelona last week, 41 innovative companies participated in the highly anticipated Innovator’s Pitch Challenge (IPC). This event provided a unique platform for early-stage life science and healthcare companies to showcase their technologies and attract potential investors.

The IPC finalists had the opportunity to deliver 4-minute pitches to an engaged audience, followed by a 9-minute Q&A session with a panel of expert investor judges. Each participating company also exhibited a poster highlighting their technology in the conference’s exhibit hall.

Many of the pitch companies and the winning companies represented the cutting-edge technology emerging from the Catalonia region, with several being member companies of Biocat, RESI Europe’s co-organizer. Biocat plays a crucial role in driving the growth of Catalonia’s life sciences and health innovation ecosystem.

The competition’s unique voting system allowed registered RESI attendees, including startup executives, early-stage investors, and industry experts, to ‘invest’ in their favorite IPC companies using RESI cash provided at check-in. Attendees based their decisions on the companies’ poster presentations and pitch performances.

Life Science Nation is proud to announce the top three winners of RESI Europe 2024’s Innovator’s Pitch Challenge:

1st Place: Gate2Brain

Jaume Baró, Executive Directorate, Enterprise and Entrepeneurship, Barcelona Activa | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series | Meritxell Teixidó, PhD, CEO & CSO, Gate2Brain | Robert Fabregat, CEO, Biocat

2nd Place: Ysotope Theranostics

shared image

3rd Place: DyCare

Jaume Baró, Executive Directorate, Enterprise and Entrepeneurship, Barcelona Activa | Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series | Ricardo Jauregui, CTO & Founder, Dycare | Robert Fabregat, CEO, Biocat

Gate2Brain, the first-place winner, will receive complimentary tickets to three RESI events of their choice, a prize valued at $12,000. The second and third-place winners will receive tickets to two and one RESI events, respectively.

For those interested in participating in the next Innovator’s Pitch Challenge, applications are now open for RESI Boston 2024. This event will take place on September 25 at the Westin Copley Place in Boston, featuring a one-day in-person conference followed by two days of virtual partnering. Early application is encouraged as spots are filled on a rolling basis.

Additionally, registration for RESI Boston is now open with super early bird rates available. Prospective attendees can save $500 by registering before Friday, July 5.

The success of RESI Europe 2024 in Barcelona, with its diverse participation and innovative format, underscores the event’s importance in connecting early-stage life science companies with potential investors and industry partners.

Comments Leave a Comment
Categories Redefining Every Stage Investments (RESI)

Hot Mandates

Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease

The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
Hot Investor Mandate 2: Hong Kong Boutique VC Firm Invests in All Kinds of Healthcare Technologies and Most Interested in Large Disease Markets of Unmet Medical Need

The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
Hot Investor Mandate 3: Strategic Investment Firm of Large Pharma Invests in Early and Late Stage Therapeutics & Drug-Device Combinations, Especially Interested in Orphan and Rare Diseases

A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
Hot Investor Mandate 4: USA-Based Investment Firm Can Invest Over $10M in Innovative Medtech and Digital Health Companies Based in Texas or Southwestern USA

The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
Hot Investor Mandate 1: Global VC Firm Headquartered in Asia Invests in All Parts of Therapeutics, Medical Devices, Diagnostics, and Digital Health

A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]

Search